229 related articles for article (PubMed ID: 22848491)
21. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation.
Chou AH; Chen YL; Hu SH; Chang YM; Wang HL
Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.
Ferrante RJ; Kubilus JK; Lee J; Ryu H; Beesen A; Zucker B; Smith K; Kowall NW; Ratan RR; Luthi-Carter R; Hersch SM
J Neurosci; 2003 Oct; 23(28):9418-27. PubMed ID: 14561870
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional and Histone Acetylation Changes Associated with CRE Elements Expose Key Factors Governing the Regulatory Circuit in the Early Stage of Huntington's Disease Models.
Arancibia-Opazo S; Contreras-Riquelme JS; Sánchez M; Cisternas-Olmedo M; Vidal RL; Martin AJM; Sáez MA
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446028
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic modifications as novel therapeutic targets for Huntington's disease.
Wang F; Fischhaber PL; Guo C; Tang TS
Epigenomics; 2014 Jun; 6(3):287-97. PubMed ID: 25111483
[TBL] [Abstract][Full Text] [Related]
25. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease.
Bobrowska A; Paganetti P; Matthias P; Bates GP
PLoS One; 2011; 6(6):e20696. PubMed ID: 21677773
[TBL] [Abstract][Full Text] [Related]
26. Early epigenomic and transcriptional changes reveal Elk-1 transcription factor as a therapeutic target in Huntington's disease.
Yildirim F; Ng CW; Kappes V; Ehrenberger T; Rigby SK; Stivanello V; Gipson TA; Soltis AR; Vanhoutte P; Caboche J; Housman DE; Fraenkel E
Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24840-24851. PubMed ID: 31744868
[TBL] [Abstract][Full Text] [Related]
27. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity.
Jia L; Berman BP; Jariwala U; Yan X; Cogan JP; Walters A; Chen T; Buchanan G; Frenkel B; Coetzee GA
PLoS One; 2008; 3(11):e3645. PubMed ID: 18997859
[TBL] [Abstract][Full Text] [Related]
28. Histone modifications in Rett syndrome lymphocytes: a preliminary evaluation.
Kaufmann WE; Jarrar MH; Wang JS; Lee YJ; Reddy S; Bibat G; Naidu S
Brain Dev; 2005 Aug; 27(5):331-9. PubMed ID: 16023547
[TBL] [Abstract][Full Text] [Related]
29. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations.
Crocker SF; Costain WJ; Robertson HA
Brain Res; 2006 May; 1088(1):176-86. PubMed ID: 16626669
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibition modulates histone acetylation at gene promoter regions and affects genome-wide gene transcription in Schistosoma mansoni.
Anderson L; Gomes MR; daSilva LF; Pereira ADSA; Mourão MM; Romier C; Pierce R; Verjovski-Almeida S
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005539. PubMed ID: 28406899
[TBL] [Abstract][Full Text] [Related]
31. Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells.
Mathew OP; Ranganna K; Yatsu FM
Biomed Pharmacother; 2010 Dec; 64(10):733-40. PubMed ID: 20970954
[TBL] [Abstract][Full Text] [Related]
32. HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.
Ooi JY; Tuano NK; Rafehi H; Gao XM; Ziemann M; Du XJ; El-Osta A
Epigenetics; 2015; 10(5):418-30. PubMed ID: 25941940
[TBL] [Abstract][Full Text] [Related]
33. Global epigenetic analysis of BDNF Val66Met mice hippocampus reveals changes in dendrite and spine remodeling genes.
Mallei A; Ieraci A; Corna S; Tardito D; Lee FS; Popoli M
Hippocampus; 2018 Nov; 28(11):783-795. PubMed ID: 30067287
[TBL] [Abstract][Full Text] [Related]
34. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.
Hockly E; Richon VM; Woodman B; Smith DL; Zhou X; Rosa E; Sathasivam K; Ghazi-Noori S; Mahal A; Lowden PA; Steffan JS; Marsh JL; Thompson LM; Lewis CM; Marks PA; Bates GP
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2041-6. PubMed ID: 12576549
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitors reverse age-related increases in side effects of haloperidol in mice.
Montalvo-Ortiz JL; Fisher DW; Rodríguez G; Fang D; Csernansky JG; Dong H
Psychopharmacology (Berl); 2017 Aug; 234(16):2385-2398. PubMed ID: 28421257
[TBL] [Abstract][Full Text] [Related]
36. The role of histone acetylation in SMN gene expression.
Kernochan LE; Russo ML; Woodling NS; Huynh TN; Avila AM; Fischbeck KH; Sumner CJ
Hum Mol Genet; 2005 May; 14(9):1171-82. PubMed ID: 15772088
[TBL] [Abstract][Full Text] [Related]
37. The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice.
Jia H; Wang Y; Morris CD; Jacques V; Gottesfeld JM; Rusche JR; Thomas EA
PLoS One; 2016; 11(3):e0152498. PubMed ID: 27031333
[TBL] [Abstract][Full Text] [Related]
38. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.
Gardian G; Browne SE; Choi DK; Klivenyi P; Gregorio J; Kubilus JK; Ryu H; Langley B; Ratan RR; Ferrante RJ; Beal MF
J Biol Chem; 2005 Jan; 280(1):556-63. PubMed ID: 15494404
[TBL] [Abstract][Full Text] [Related]
39. Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.
Moumné L; Campbell K; Howland D; Ouyang Y; Bates GP
PLoS One; 2012; 7(2):e31080. PubMed ID: 22347433
[TBL] [Abstract][Full Text] [Related]
40. Transcriptional dysregulation in Huntington's disease: The role of histone deacetylases.
Sharma S; Taliyan R
Pharmacol Res; 2015 Oct; 100():157-69. PubMed ID: 26254871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
